Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 7/20 | 0.69 |
| ▸ | AKR1C2 | P52895 | 7/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.50 |
| ▸ | CDC42 | P60953 | 1/20 | 0.50 |
| ▸ | RAC1 | P63000 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3829820 | 0.84 | HTT (0.59) | KDM4ETP53CYP3A4SMN1; SMN2TDP1 | |
| SCHEMBL17806176 | 0.84 | AKR1C3 (0.49) | AKR1C3AKR1C2PTGS1LMNAMAPT | |
| SCHEMBL3175855 | 0.82 | CTBP2 (0.57) | CYP1A2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL18883075 | 0.82 | AKR1C3 (0.47) | AKR1C3AKR1C2PTGS1LMNAMAPT | |
| SCHEMBL10536961 | 0.81 | AKR1C3 (0.75) | AKR1C3AKR1C2PTGS1LMNAMAPT | |
| 6-Methoxy-2-Naphthylacetic Acid SCHEMBL253759 | 0.81 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1LMNAMAPT | |
| SCHEMBL10137777 | 0.81 | CYP1A2 (0.53) | CYP1A2SLC6A3MEN1KMT2AL3MBTL1 | |
| 6-Methoxy-2-Naphthylacetic Acid SCHEMBL9504321 | 0.80 | PTGS1 (0.73) | AKR1C3AKR1C2PTGS1LMNAMAPT | |
| SCHEMBL9580307 | 0.80 | PTGS1 (0.73) | AKR1C3AKR1C2PTGS1LMNAMAPT | |
| 6-Methoxy-2-Naphthylacetic Acid SCHEMBL9504307 | 0.80 | AKR1C3 (0.97) | AKR1C3AKR1C2PTGS1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016799-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | MEDICON PHARMACEUTICALS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240016799-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | MEDICON PHARMACEUTICALS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-11752146-B2 | Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof | MEDICON PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11752146-B2 | Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof | MEDICON PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20200246330-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | MEDICON PHARMACEUTICALS, INC. (US) | 2020-08-06 | — | — | US | disclosed |
| US-20150306232-A1 | HYDROGELATORS COMPRISING D-AMINO ACIDS | BRANDEIS UNIVERSITY | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150306232-A1 | HYDROGELATORS COMPRISING D-AMINO ACIDS | DNPEP, S100A10, S100A11 | AKR1C3 4569/4885AKR1C2 4506/4885PTGS1 239/4885 |
| US-20200246330-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | VEGFA, HPGDS, ALOX5 | AKR1C3 1203/4885AKR1C2 1615/4885PTGS1 9/4885 |
| US-11752146-B2 | Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof | VEGFA, HPGDS, ALOX5 | AKR1C3 1203/4885AKR1C2 1615/4885PTGS1 9/4885 |
| US-20240016799-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | VEGFA, HPGDS, ALOX5 | AKR1C3 1203/4885AKR1C2 1615/4885PTGS1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.